Verve Therapeutics Inc. has been one of the first to involve CRISPR gene editing with lowering cholesterol levels. A newer version of CRISPR, also known as base editing, has allowed many scientists to edit certain nucleotides in our DNA. Verve’s researchers are editing the PCSK9 gene through CRISPR, which is requisite for LDL production. Click here to learn about some of the patients involved in the ongoing trial.